98%
921
2 minutes
20
Background: As the Japanese population may have less genetic diversity than other ethnic groups, treatment outcomes may be affected when allogeneic hematopoietic cell transplantation is performed in other races. However, evidence explaining the effect of racial differences is limited.
Methods: We used the Japanese National Database to examine the outcomes of first allogeneic bone marrow transplantations (BMTs) performed between Japanese and non-Japanese patients from 1996 to 2021. We performed propensity score matching using sex, age group, underlying disease group, HLA mismatch, conditioning regimen intensity, and BMT implementation age to select Japanese-to-Japanese BMT patients as the controls.
Results: The numbers of non-Japanese-to-Japanese and Japanese-to-non-Japanese BMT cases included in the analysis were 48 and 75, respectively, and the following outcomes were compared: overall survival, non-relapse mortality, acute graft-vs-host disease (GVHD) ≥ grade II, chronic GVHD, and engraftment of neutrophils and platelets. Most parameters did not differ when comparing BMTs according to ethnicity; only platelet engraftment was delayed in Japanese-to-non-Japanese BMT but not in non-Japanese-to-Japanese BMT.
Conclusions: The results of this study suggested that BMT performed in Japanese and non-Japanese patients has little effect on treatment outcomes. The results of this study may be useful for donor selection in Japan, where internationalization has progressed in recent years.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.transproceed.2024.01.049 | DOI Listing |
J Dermatol Sci
August 2025
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Background: Extramammary Paget's disease (EMPD) occurs in areas where apocrine glands are abundant. EMPD is associated with the known somatic hotspot mutation g.chr14:38064406 G>A in the promoter region of FOXA1 and S310F in ERBB2.
View Article and Find Full Text PDFInt J Hematol
August 2025
Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin. The safety of CPX-351 in Japanese patients was verified by comparing safety data from the Japanese phase 1/2 study and the global phase 3 study. This analysis included 47 patients in the safety analysis set of the Japanese study and 153 patients who received CPX-351 and were included in the intention-to-treat analysis for the global study.
View Article and Find Full Text PDFJpn J Radiol
July 2025
Clinical Development Department, Guerbet, Roissy CDG Cedex, France.
Purpose: The aim of this study was to evaluate the pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers. A population-based pharmacokinetic approach was used to compare pharmacokinetic parameters with a non-Japanese adult population.
Materials And Methods: In this double-blind, placebo-controlled phase I study, Japanese healthy volunteers were randomized to receive gadopiclenol (at 0.
Eur J Intern Med
July 2025
Sana Kliniken Lübeck, Lübeck, Germany.
Empagliflozin and dapagliflozin, frequently prescribed Sodium-Glucose- Cotransporter2-inhibitors (SGLT2i), are now also recommended for nondiabetic patients with heart failure (HF). Since concerns exist about myopathy and sarcopenia as adverse effects of SGLT2i, the review summarizes effects of dapagliflozin and empagliflozin on skeletal muscle. PubMed was searched for "SGLT2" OR "SGLT2 inhibitors" OR "SGLT2i" OR "dapagliflozin" OR "empagliflozin" AND "myopathy" OR "sarcopenia" OR "skeletal muscle" OR "muscle loss" OR "muscle weakness" OR "muscle wasting" OR "myotoxicity" OR "muscle atrophy" OR "rhabdomyolysis".
View Article and Find Full Text PDFCureus
June 2025
Microbiology, Assam Medical College, Dibrugarh, IND.
Background: Northeast India is endemic for Japanese encephalitis (JE), which causes acute encephalitis syndrome (AES). Though there is no specific therapy for JE, many etiological agents of AES are treatable. Hence, this study aims to evaluate the AES cases for their etiologies, laboratory parameters, and associated clinical manifestations.
View Article and Find Full Text PDF